AstraZeneca’s Imfinzi receives European approval to treat patients with resectable muscle-invasive bladder cancer: Cambridge, UK Saturday, July 5, 2025, 09:00 Hrs [IST] AstraZen ...

It comes amid reports that the drugs maker is considering moving its listing from the UK to the US in what would be a hammer ...

It killed around 97,000 women in the same year. Imfinzi is currently approved for lung and biliary tract tumours, while Lynparza is used to treat ovarian, breast, pancreatic, and prostate cancer.

AstraZeneca recently claimed approval in the US for Imfinzi (durvalumab) as neoadjuvant/adjuvant therapy for stage 2a to 3b NSCLC while Bristol-Myers Squibb also has positive phase 3 results with ...

As Britain sweltered in the hottest June on record, businesses and homeowners invested in technology to make our living ...

Approval based on NIAGARA Phase III trial results which showed a 32% reduction in the risk of recurrence and a 25% reduction in the risk of death for the ...